Skip to content
Steady
Get Steady
HomeMounjaro tracker
Mounjaro trackerTirzepatide

The Mounjaro tracker built for women on tirzepatide.

Two receptors, more average weight loss, and one drug-specific contraception note most women don't hear from their prescriber.

Free to start. Subscription unlocks the full app. iPhone only.

Free to startiPhone onlyNo adsPrivate by design

Mounjaro is tirzepatide, prescribed for type-2 diabetes. It is the dual GLP-1 / GIP receptor agonist, the second receptor is the reason average weight loss on tirzepatide is roughly 50 percent higher than on semaglutide in the head-to-head SURMOUNT-5 trial.

Mounjaro has a titration ladder that climbs through 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly. Steady has all six dose steps built in, supports pausing the climb at any step, and tracks the side-effect pattern that tends to differ from semaglutide, slightly more constipation, slightly more early-titration nausea.

Where Mounjaro warrants extra attention for women: oral contraceptives. The Eli Lilly label is explicit that tirzepatide can reduce the absorption of oral contraceptive pills, especially in the four-week window after starting and after each dose increase. Steady surfaces this at exactly the moments it matters, calmly, with a link to the relevant guidance.

What’s inside

Built around how this medication actually works.

Feature

All six dose steps

2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg. Pause supported at any step. The titration is a decision.

Feature

The contraception note

Tirzepatide can reduce oral contraceptive absorption. Steady surfaces the four-week barrier window after every dose escalation.

Feature

Constipation, handled

Mounjaro causes more constipation than semaglutide on average. The fibre-water-magnesium-movement protocol is built into the coach.

Feature

Six-site injection rotation

Abdomen, thigh, upper arm, both sides. Six weeks per site, every site clean.

The research behind it

What the studies actually say.

Evidence-based summaries of the papers that informed every part of this page. Each article cites its sources.

Mounjaro

Mounjaro vs Wegovy: how to think about the choice

Tirzepatide loses more weight on average. Semaglutide has more years of safety data. The right answer is rarely about averages, here's the framework your prescriber is probably…

Read the article
Mounjaro

GLP-1s and the pill: a warning women on Mounjaro and Zepbound need to read

Tirzepatide can reduce the effectiveness of oral contraceptives. The label is clear about it; the conversation often isn't. Here is what to know, what to switch to, and for how…

Read the article
Dosing

Pausing your titration: the dose-hold most prescribers don't mention

Standard GLP-1 protocols climb the dose every four weeks. Nothing in the label requires that. The pause that protects skin, muscle, and mood is one of the most useful, and least…

Read the article
Side effects

Constipation on a GLP-1: the fibre, water, magnesium loop that actually works

Slower gastric emptying is how GLP-1s work. It is also why a third of women on the drug develop constipation. Here is the protocol that fixes it without bringing back hunger.

Read the article
Injection

How to rotate your GLP-1 injection sites, and why it matters more than you think

Always the same spot. Always the same time. Always the same low-grade lump under the skin. Here is the rotation pattern that prevents lipohypertrophy, and the technique notes most…

Read the article
Pregnancy

GLP-1s and pregnancy: the two-month wash-out you need to plan for

GLP-1s are not approved for use in pregnancy. The standard guidance is to stop the medication two months before trying to conceive. Here is the reasoning, the gap in the data, and…

Read the article
Get the app

The GLP-1 tracker for women. Free on the App Store.

Built around how your body actually works on Ozempic, Wegovy, Mounjaro and Zepbound. iPhone only, for now.

Free to start. Subscription unlocks the full app. iPhone only.

Free to startiPhone onlyNo adsPrivate by design